UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2017
CYTOMX THERAPEUTICS, INC.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware |
001-37587 |
27-3521219 |
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
151 Oyster Point Blvd.
Suite 400
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
|
|
|
|
Registrant’s telephone number, including area code: (650) 515-3185
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
|
Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ |
Item 2.02.Results of Operations and Financial Condition.
On August 7, 2017, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release announcing its unaudited financial results for the three and six months ended June 30, 2017 and its unaudited financial position as of June 30, 2017. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Item 2.02 of this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
|
Item 9.01 |
Financial Statements and Exhibits. |
Reference is made to the Exhibit Index attached hereto
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
Date: August 7, 2017 |
|
|
CYTOMX THERAPEUTICS, INC. |
||||
|
|
|
|
|
||||
|
|
|
|
|
By: |
|
/s/ Cynthia J. Ladd |
|
|
|
|
|
|
|
|
Cynthia J. Ladd |
|
|
|
|
|
|
|
|
Senior Vice President and General Counsel |
|
|
Exhibit No. |
|
Description |
|
99.1 |
|
Press release titled “CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call” issued by CytomX Therapeutics, Inc. on August 7, 2017. |
|
|
|
|
|
|
|
|
Exhibit 99.1
CytomX Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call
Strong Pipeline Momentum Continues
Initiated Combination Arms in Phase 1/2 PROCLAIM-CX-072 Study
Initiated Phase 1/2 PROCLAIM-CX-2009 Study
SOUTH SAN FRANCISCO, Calif., August 7, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, today reported second quarter 2017 financial results.
As of June 30, 2017, CytomX had cash, cash equivalents and short-term investments of $335.9 million. Based upon its current operating plan, the Company expects its existing capital resources will be sufficient to fund operations into 2020.
“During the second quarter, our pipeline of innovative Probody therapeutics continued to advance. We now have two wholly owned product candidates in clinical studies - CX-072, a PD-L1-targeting Probody therapeutic, and CX-2009, a Probody drug conjugate that targets the novel, highly expressed tumor antigen, CD-166,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX Therapeutics. "We remain on track to disclose data from these initial Probody clinical trials in 2018, and also expect clinical trial initiation for two partnered programs during this timeframe.”
Q2’17 BUSINESS HIGHLIGHTS AND RECENT DEVELOPMENTS
PROCLAIM-CX-072 (PD-L1 Probody) Clinical Program
|
|
• |
Patient enrollment has progressed well in the monotherapy dose escalation arm of the study evaluating CX-072 in patients with advanced unresectable solids tumors or lymphomas. This arm was initiated in 1Q’17 and enrollment is expected to be completed in 2H ’17. |
|
|
• |
Patient enrollment has been initiated in a combination arm of the study evaluating a concomitant schedule for CX-072 plus ipilimumab in patients with advanced unresectable solids tumors or lymphomas. |
|
|
• |
Patient enrollment has also been initiated in a vemurafenib combination arm, evaluating CX-072 plus vemurafenib in patients with V600E BRAF-positive melanoma. |
|
|
• |
During the first half of 2018, an expansion cohort of the study at the recommended Phase 2 dose is expected to begin enrolling patients to |
|
|
evaluate CX-072 as monotherapy in a tumor type with known sensitivity to PD-L1 and/or PD-1 inhibitors. |
PROCLAIM-CX-2009 (CD166 Probody Drug Conjugate) Clinical Program
|
|
• |
Patient enrollment is underway in the PROCLAIM-CX-2009 study, a Phase 1/2 clinical trial evaluating CX-2009 as monotherapy in a subset of CD166-positive cancers. |
|
|
• |
CX-2009 is a first-in-class Probody drug conjugate (PDC) that targets CD-166, an antigen that is broadly and highly expressed in many types of cancers, but has been considered undruggable given that it is also expressed in normal tissue. |
|
|
• |
CX-2009 has broad potential across multiple solid tumor types and is the first PDC to enter the clinic. |
CX-2029 Preclinical Program (Co-Development Partnership with AbbVie)
|
|
• |
CX-2029, a first-in-class PDC-targeting CD71 being developed by CytomX in collaboration with AbbVie, was advanced into GLP toxicology studies, resulting in a $15 million milestone payment from AbbVie to CytomX to be received during the 3Q’17. |
|
|
• |
CD71, otherwise known as the transferrin receptor, is a high potential target, which, like CD166, has previously been considered undruggable given its expression and function in normal tissues. |
|
|
• |
CytomX remains on track to file an IND for CX-2029 in 2018. |
Bristol-Myers Squibb (BMS) Partnership
|
|
• |
BMS is progressing IND-enabling studies for a CTLA-4-directed Probody therapeutic discovered within the collaboration and expects to initiate a clinical trial in early 2018. |
|
|
• |
During the second quarter, CytomX recognized receipt of a $200 million upfront payment under the previously announced expansion of the Bristol-Myers Squibb worldwide collaboration. |
|
|
• |
BMS selected its fifth target in the collaboration, the first under the newly expanded agreement. BMS has now selected five of ten available oncology targets. |
Second Quarter Financial Results
Cash, cash equivalents and investments totaled $335.9 million as of June 30, 2017, compared to $181.9 million as of December 31, 2016. The increase reflects a $200 million upfront payment received from BMS in connection with the expansion of the existing collaboration.
Revenue was $8.8 million for the three months ended June 30, 2017, compared to $3.1 million for the three months ended June 30, 2016. The increase was primarily attributable to recognized revenue from the upfront payment received from BMS in connection with the expansion of the existing collaboration.
Research and development expenses were $28.1 million for the three months ended June 30, 2017, compared to $12.7 million for the three months ended June 30, 2016. The increase was primarily attributable to a $10.0 million sublicense payment made to UCSB, which was triggered by the receipt of the $200 million upfront payment from BMS in connection with the expanded collaboration, an increase of $2.8 million to advance the Company’s CX-072 and CX-2009 into Phase 1/2 clinical development, an increase of $1.0 million in milestone payments to UCSB triggered by the development of CX-2009, an increase of $1.0 million in facilities-related expenses, and an increase of $0.8 million in personnel-related expenses due to an increase in headcount.
General and administrative expenses were $6.0 million for the three months ended June 30, 2017, compared to $4.6 million for the three months ended June 30, 2016. The increase was attributable to $0.6 million in personnel-related expenses due to an increase in headcount, an increase of $0.4 million in severance payment, and an increase of $0.3 million in facilities-related expenses.
Conference Call/Webcast Information
In conjunction with today’s financial results announcement, the Company will provide a mid-year update via webcast or teleconference. Interested parties may access the live audio webcast of the teleconference today at 5:00 p.m. ET through the Investor and News page of CytomX's website at http://ir.cytomx.com or by dialing 1-877-809-6037 and using the passcode 61956517. A replay will be available on the CytomX website or by dialing 1-855-859-2056 and using the passcode 61956517. The replay will be available from August 7, 2017, until August 14, 2017.
About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on Twitter.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond our control, and may cause the
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements. Accordingly, you should not rely on any of these forward-looking statements, including those relating to the potential efficacy of CytomX’s product candidates, administered separately or in combination , CytomX’s ability and the ability of its collaborative partners to develop and advance product candidates into and successfully complete clinical trials, including CytomX’s Phase 1/2 clinical trials of CX-072 and CX-2009 and the timing of any future clinical trials to be initiated by CytomX or any of its collaborative partners. Two of our product candidates under our Probody platform are in the initial stages of clinical development and our other product candidates are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties. Projected net cash utilization and capital resources are subject to substantial risk of variance based on a wide variety of factors that can be difficult to predict. Applicable risks and uncertainties include those relating to our preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on August 7, 2017. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
Media Contact:
Spectrum
Christine Quern
cquern@spectrumscience.com
202-587-2588
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(in thousands, except share and per share data)
(unaudited)
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
||||||||||
|
|
|
June 30, |
|
|
June 30, |
|
||||||||||
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
||||
|
|
|
|
|
|
|
|
||||||||||
|
Revenues |
|
$ |
8,283 |
|
|
$ |
2,539 |
|
|
$ |
19,459 |
|
|
$ |
4,322 |
|
|
Revenues from related party |
|
|
469 |
|
|
|
555 |
|
|
|
946 |
|
|
|
995 |
|
|
Total revenues |
|
|
8,752 |
|
|
|
3,094 |
|
|
|
20,405 |
|
|
|
5,317 |
|
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
28,076 |
|
|
|
12,705 |
|
|
|
42,652 |
|
|
|
26,070 |
|
|
General and administrative |
|
|
6,049 |
|
|
|
4,647 |
|
|
|
11,740 |
|
|
|
9,687 |
|
|
Total operating expenses |
|
|
34,125 |
|
|
|
17,352 |
|
|
|
54,392 |
|
|
|
35,757 |
|
|
Loss from operations |
|
|
(25,373 |
) |
|
|
(14,258 |
) |
|
|
(33,987 |
) |
|
|
(30,440 |
) |
|
Interest income, net |
|
|
357 |
|
|
|
195 |
|
|
|
594 |
|
|
|
332 |
|
|
Other income (expense), net |
|
|
(174 |
) |
|
|
(110 |
) |
|
|
(54 |
) |
|
|
(91 |
) |
|
Loss before provision for income taxes |
|
|
(25,190 |
) |
|
|
(14,173 |
) |
|
|
(33,447 |
) |
|
|
(30,199 |
) |
|
Provision for income taxes |
|
|
26 |
|
|
|
3 |
|
|
|
26 |
|
|
|
6 |
|
|
Net loss |
|
$ |
(25,216 |
) |
|
$ |
(14,176 |
) |
|
$ |
(33,473 |
) |
|
$ |
(30,205 |
) |
|
Net loss per share, basic and diluted |
|
$ |
(0.69 |
) |
|
$ |
(0.39 |
) |
|
$ |
(0.91 |
) |
|
$ |
(0.84 |
) |
|
Shares used to compute net loss per share, basic and diluted |
|
|
36,780,897 |
|
|
|
36,113,363 |
|
|
|
36,660,548 |
|
|
|
36,088,393 |
|
(in thousands, except share and per share data)
(unaudited)
|
|
|
June 30, |
|
|
December 31, |
|
||
|
|
|
2017 |
|
|
2016 |
|
||
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
272,860 |
|
|
$ |
104,645 |
|
|
Short-term investments |
|
|
63,056 |
|
|
|
77,293 |
|
|
Accounts receivable |
|
|
158 |
|
|
|
2,159 |
|
|
Related party accounts receivable |
|
|
27 |
|
|
|
154 |
|
|
Prepaid expenses and other current assets |
|
|
4,579 |
|
|
|
3,896 |
|
|
Total current assets |
|
|
340,680 |
|
|
|
188,147 |
|
|
Property and equipment, net |
|
|
4,319 |
|
|
|
4,392 |
|
|
Intangible assets |
|
|
1,750 |
|
|
|
1,750 |
|
|
Goodwill |
|
|
949 |
|
|
|
949 |
|
|
Restricted cash |
|
|
917 |
|
|
|
917 |
|
|
Other assets |
|
|
3,240 |
|
|
|
2,973 |
|
|
Total assets |
|
$ |
351,855 |
|
|
$ |
199,128 |
|
|
Liabilities and Stockholders' Equity |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
6,364 |
|
|
$ |
6,596 |
|
|
Accrued liabilities |
|
|
7,499 |
|
|
|
8,824 |
|
|
Deferred revenues, current portion |
|
|
46,772 |
|
|
|
20,347 |
|
|
Total current liabilities |
|
|
60,635 |
|
|
|
35,767 |
|
|
Deferred revenue, net of current portion |
|
|
237,053 |
|
|
|
83,803 |
|
|
Deferred tax liability |
|
|
539 |
|
|
|
513 |
|
|
Other long-term liabilities |
|
|
1,391 |
|
|
|
566 |
|
|
Total liabilities |
|
|
299,618 |
|
|
|
120,649 |
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
|
Preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding at June 30, 2017 and December 31, 2016. |
|
|
— |
|
|
|
— |
|
|
Common stock, $0.00001 par value; 75,000,000 shares authorized; 36,839,342 and 36,490,169 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively |
|
|
1 |
|
|
|
1 |
|
|
Additional paid-in capital |
|
|
262,185 |
|
|
|
254,871 |
|
|
Accumulated other comprehensive loss |
|
|
(110 |
) |
|
|
(27 |
) |
|
Accumulated deficit |
|
|
(209,839 |
) |
|
|
(176,366 |
) |
|
Total stockholders' equity |
|
|
52,237 |
|
|
|
78,479 |
|
|
Total liabilities and stockholders' equity |
|
$ |
351,855 |
|
|
$ |
199,128 |
|